ReviewInternational journal of molecular sciences2019
Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Utility of iRECIST for evaluating treatment efficacy in patients receiving immune checkpoint inhibitors.Journal of gynecologic oncology · 2026Article
- Small intestine choriocarcinoma with brain, lung and liver metastases in a male patient: a case report.Frontiers in oncology · 2026Article
- A New Direction in Endometrial Cancer Therapy-PD-1 and PD-L1 Immune Checkpoint Inhibitors-Where Will It Take Us?Journal of clinical medicine · 2025Review
- Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials.Immunotherapy · 2025Review
- Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer.Brain, behavior, & immunity - health · 2022Article
- BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer.International journal of molecular sciences · 2022Article
- Review
- Neuroendocrine Neoplasms of the Gynecologic Tract.Cancers · 2022Review
- Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers.Molecular therapy oncolytics · 2022Review
- Construction of novel hypoxia-related gene model for prognosis and tumor microenvironment in endometrial carcinoma.Frontiers in endocrinology · 2022Article
- Combinations of radiotherapy with immunotherapy in cervical cancer.Journal of Cancer · 2022Review
- Identification of Alternative Splicing-Related Genes CYB561 and FOLH1 in the Tumor-Immune Microenvironment for Endometrial Cancer Based on TCGA Data Analysis.Frontiers in genetics · 2022Article
- Monoclonal antibodies in cervical malignancy-related HPV.Frontiers in oncology · 2022Review
- Pembrolizumab in endometrial cancer: Where we stand now.Oncology letters · 2021Review
- Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know.Korean journal of radiology · 2021Review
- An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab.Gynecologic oncology reports · 2021Article
- Article
- An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.Cancer gene therapy · 2021Article
- The role of an immune signature for prognosis and immunotherapy response in endometrial cancer.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite the ongoing progress in cancer research, the global cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018. Gynecological cancers, such as ovarian, endometrial, and cervical cancers, considerably contribute to global cancer burden, leading to $5,862.6, $2,945.7, and $1,543.9 million of annual costs of cancer care, respectively. Thus, the development of effective therapies against gynecological cancers is still a largely unmet medical need. One of the novel therapeutic approaches is to induce anti-cancer immunity by the inhibition of the immune checkpoint pathways using monoclonal antibodies. The molecular targets for monoclonal antibodies are cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed death-ligand 1 (PD-L1). The rationale for the use of immune checkpoint inhibitors in patients with gynecological cancers was based on the immunohistological studies showing high expression levels of PD-1 and PD-L1 in those cancers. Currently available immune checkpoint inhibitors include nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, and ipilimumab. The efficacy and safety of these inhibitors, used as monotherapy and with combination with chemotherapy, is being currently evaluated in several clinical studies. As the results are promising, more clinical trials are being planned, which may lead to the development of efficient therapies for gynecological cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.